Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extra numbing shot may ease pain of prostate biopsy

NCT ID NCT07683182

Symptom relief Sponsor: Marmara University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether adding an extra numbing injection inside the prostate can reduce pain during a prostate biopsy. Fifty men undergoing the procedure will receive either standard numbing of the skin or the standard plus the extra injection. Pain levels are measured before, during, and after the biopsy using a simple 0-to-10 scale. The goal is to find a better way to keep patients comfortable during this common cancer-screening procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prilocaine and bupivacaine (local anesthetics)
What this could lead to
If effective, this technique could make prostate biopsy less painful and more tolerable for patients.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply to all patients. Adding extra anesthesia could also carry its own risks, such as discomfort or rare side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male patients aged 18 years or older * Clinical indication for transperineal prostate biopsy based on elevated prostate-specific antigen (PSA) level and/or suspicious digital rectal examination findings * Ability to understand and complete the Hospital Anxiety and Depression Scale (HADS) * Ability to provide pain scores using a 10-point Visual Analog Scale (VAS) * Provision of written informed consent Exclusion Criteria: * Previous history of prostate biopsy * Known hypersensitivity or contraindication to local anesthetic agents * Hematological disorders affecting coagulation * Active urinary tract infection * Neurological disorders that may affect pain perception * Psychiatric disorders that may affect pain assessment or completion of study -questionnaires * Inability to complete the HADS questionnaire or VAS assessment * Refusal to participate or inability to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer (diagnosis) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer (diagnosis) Prostate specific antigen

Contacts and locations

Locations

  • Marmara University School of Medicine

    Istanbul, Pendik, 34722, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.